Year: 2014-15
Company: City of Hope
Liaison(s): John Yim
City of Hope is a comprehensive cancer center with advanced research and treatment options for cancer patients. Currently there are 41 comprehensive cancer centers comprised of doctors, research scientists, and business professionals who all believe in conducting innovative research, eliminating diseases, and finding cures to alleviate pain and side effects. Dr. John Yim is currently evaluating a strong anticancer molecule (“Product Y”). The traditional patent protection route for the Product Y therapeutic is clouded because of its natural product source. However, due to the molecule’s potent anti-cancer promise, the City of Hope would like to determine if there is a business model that makes sense for “Product Y.” Finally, if there is an appropriate business model the team has been asked to identify the optimal clinical, regulatory, and commercial paths to make this compound available to patients and physicians. The COH TMP team was tasked with investigating the field of natural chemotherapeutic remedies to identify market leaders, drivers, and other factors as well as a comprehensive analysis of regulatory pathway options that could bring “Product Y” to clinical trials. To accomplish this objective, the COH TMP Team examined the regulatory landscape for equivalent natural products in the US and provided a strategic recommendation for “Product Y.” In addition, the Team identified the current market opportunities through primary and secondary market research. In the final report and analysis, the TMP Team has provided the City of Hope with recommendations which prioritize the market entry point for “Product Y” based on current unmet needs in cancer treatment and commercial potential.
Celebrating 25 years of innovation! 25.kgi.edu.